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Abstract
Aim
Statins decrease cardiovascular complications, but can induce myopathy. Here, we explored the 
implication of PGC-1α in statin-associated myotoxicity. 
Methods
We treated PGC-1α knockout (KO), PGC-1α over-expression (OE) and wild-type mice (WT) mice 
orally with 5 mg simvastatin kg-1 day-1 for 3 weeks and assessed muscle function and 
metabolism. 
Results
In WT and KO mice, but not in OE mice, simvastatin decreased grip strength, maximal running 
distance and vertical power assessed by ergometry. Post exercise plasma lactate concentrations 
were higher in WT and KO compared to OE mice. In glycolytic gastrocnemius, simvastatin 
decreased mitochondrial respiration, increased mitochondrial ROS production and free radical 
leak in WT and KO, but not in OE mice. Simvastatin increased mRNA expression of Sod1 and 
Sod2 in glycolytic and oxidative gastrocnemius of WT, but decreased it in KO mice. OE mice had 
a higher mitochondrial DNA content in both gastrocnemius than WT or KO mice and simvastatin 
exhibited a trend to decrease the citrate synthase activity in white and red gastrocnemius in all 
treatment groups. Simvastatin showed a trend to decrease the mitochondrial volume fraction in 
both muscle types of all treatment groups. Mitochondria were smaller in WT and KO compared to 
OE mice and simvastatin further reduced the mitochondrial size in WT and KO mice, but not in 
OE mice. 
Conclusions
Simvastatin impairs skeletal muscle function, muscle oxidative metabolism and mitochondrial 
morphology preferentially in WT and KO mice, whereas OE mice appear to be protected, 
suggesting a role of PGC-1α in preventing simvastatin-associated myotoxicity.
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1 Introduction
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are effective low density 
lipoprotein (LDL)-cholesterol lowering drugs and belong to the most often prescribed medications 
in developed countries 1. They reduce hepatic cholesterol synthesis by inhibiting the synthesis of 
mevalonate, the rate-limiting step in the cholesterol biosynthetic pathway 2. Although the clinical 
benefits of statins in LDL-cholesterol lowering are well established, patients may suffer from 
muscle toxicity (termed statin-associated muscle symptoms, SAMS) 3, which affects up to 1 in 4 
patients treated with statins. The clinical severity of SAMS ranges from asymptomatic elevation of 
creatine kinase (CK) activity to fatal rhabdomyolysis. 
Our knowledge about the mechanisms of statin induced skeletal muscle injury is currently 
incomplete 4. Several studies have suggested that mitochondria may play a role in statin-induced 
myotoxicity. By inhibiting the synthesis of mevalonate, statins impair the production of coenzyme 
Q, which is an important constituent of the electron transport chain 5. Coenzyme Q deficiency 
may therefore be a cause for mitochondrial toxicity of statins, but its contribution to myotoxicity of 
statins is debated 4,6. In addition, several studies have shown that statins can inhibit the function 
of the electron transport chain directly by inhibiting the function of enzyme complexes of the 
electron transport 3,7-9. Mitochondria not only produce energy in the form of ATP, but are also 
important generators of reactive oxygen species (ROS), which can act either as a second 
messenger or as a source of cellular damage, depending on the amount ROS being produced 10-
13. In support of a role of mitochondrial ROS for statin-induced myopathy, we have shown in a 
previous study that treatment of rats with atorvastatin impaired the activity of enzyme complexes 
of the electron transport chain, increased skeletal muscle ROS and decreased exercise capacity 
9.
The peroxisome proliferator-activated receptor gamma co-activator (PGC-1) is a major regulator 
of mitochondrial biogenesis and represents a potential target for the effects of statins on skeletal 
muscle 14. In support of this assumption, we have shown previously that statins impair 
mitochondrial biogenesis in skeletal muscle of both patients suffering from SAMS as well as in 
rats 15. Since over-expression of PGC-1 increases number and function of mitochondria in 
skeletal muscle 16 as well as the number of type IIa and type I oxidative slow twitch high 
endurance muscle fibers and endurance performance 17, PGC-1α over-expression may be able to 
prevent statin-associated myotoxicity. In contrast, statin-associated myotoxicity may be more 
accentuated in mice lacking PGC-1α.
Based on these considerations, we hypothesize that statins should decrease the physical 
performance of mice through skeletal muscle mitochondrial impairment, and that over-expression 
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myotoxicity compared to wild type mice. In the current study, we therefore investigated the effect 
of simvastatin on skeletal muscle function and muscle energy metabolism in wild-type mice (WT), 
PGC-1 muscle knock-out mice (KO mice) and in mice over-expressing PGC-1 (OE mice). 
Control mice for each group were treated with vehicle (water).
2 Results
2.1 Simvastatin treatment did not change physiological parameters.
In order to assess possible changes in the overall physical condition of the mice, each mouse 
was monitored for body weight as well as food and water intake during the entire three weeks of 
treatment with either simvastatin or water (Table 1). After 3 weeks, a daily oral dose of 5 mg x kg-
1 simvastatin did not affect the parameters mentioned above. The heart weight and the weight of 
the gastrocnemius and extensor digitorum longus (EDL) muscles were also not affected by the 
treatment with simvastatin. However, in WT mice, treatment with simvastatin was associated with 
an increase in the weight of the soleus muscle (Table 1). PGC-1 knockout or over-expression 
influenced the muscle weight only slightly. OE mice treated with water had a higher weight of the 
soleus muscle and a lower weight of quadriceps muscle compared to the respective WT mice.
2.2 Plasma concentration of simvastatin was similar in WT, PGC-1 KO and OE mice.
Exposure to simvastatin in mice was analyzed in plasma by LC-MS/MS. As expected, we did not 
detect any simvastatin in plasma from mice treated with water. In mice treated with simvastatin, 
there was no significant difference between WT (average 14.7, range 9.68 – 21.3 nM), KO 
(average 7.11, range 3.78 – 11.7 nM), and OE mice (average 7.05, range 1.88 – 13.4 nM). The 
plasma concentrations were comparable to values measured in patients 18.
2.3 Simvastatin treatment decreased grip strength in WT and PGC-1 KO mice, but not in 
PGC-1 OE mice.
To monitor mouse physical strength, we measured their grip strength once a week during the 
three weeks of treatment. Each grip strength was normalized to body weight at the day of grip 
strength measurement. Grip strength measurements obtained during treatment were compared 
to the initial grip strength at day 1 (set to 100% for control WT mice). Control mice in the WT, KO 
and OE groups showed stable grip strength over time, while mice treated with simvastatin 
showed a gradual decrease, which reached statistical significance at day 22 in WT mice (Figure 
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2.4 Simvastatin treatment decreased physical capacity in WT and PGC-1 KO mice, but 
not in PGC-1 OE mice.
To evaluate muscle endurance, mice were stimulated to run on a treadmill until exhaustion 
(Figure 2A). In comparison to WT mice, KO mice ran a significantly shorter and OE mice a longer 
distance. Simvastatin decreased the running distance in WT and KO mice in comparison to their 
respective control mice, but showed no effect in OE mice (Figure 2A). Based on these data, we 
calculated the vertical mechanical power of the mice exerted during exercise (Figure 2B). In 
comparison to WT mice, KO mice developed less and OE mice more vertical power. We found no 
difference between simvastatin-treated and control mice in both WT and OE mice. However, 
simvastatin decreased vertical power exerted by KO mice (Figure 2B).
To further explain the differences in running distance between mice, we measured their plasma 
lactate concentration before and after exercise. Before exercise, lactate concentrations were 
similar in all groups (Figures 2C - 2E). Exercise increased the plasma lactate concentrations in all 
groups, but this increase was clearly lower in OE mice than in WT or KO mice. WT mice treated 
with simvastatin had a significantly higher post-exercise plasma lactate concentration than the 
respective control mice (Figure 2C). In the other groups, simvastatin did not affect the post-
exercise plasma lactate concentration (Figures 2D and 2E). 
To better understand the plasma lactate levels in mice after exercise, we checked the mRNA 
expression of the lactate transporters Mct1 and Mct4 involved in lactate import and export, 
respectively, in skeletal muscle. We observed mouse model effects on the mRNA expression on 
both Mct1 and Mct4 transporters in OE mice, with Mct1 being upregulated (Suppl. Figure 1A) and 
Mct4 downregulated (Suppl. Figure 1B) in glycolytic gastrocnemius. These data support the 
notion that the low lactate plasma levels in OE mice were not only due to a lower production in 
skeletal muscle, but also due to increased lactate reuptake from the blood.
Electrical shocks, which stimulated the mice to run, were measured during exercise on the 
treadmill. Simvastatin treated mice from both WT and KO groups displayed a curve shifted to the 
left in comparison to their respective control mice (Suppl. Figures 2A and 2B), which correlated 
with the shorter running distance. In comparison, treatment with simvastatin did not affect the 
number of shocks in OE mice (Suppl. Figure 2C). In order to analyze these graphs further, we 
calculated the time for the mice to reach 40 cumulative shocks. KO mice reached the 40 shocks 
threshold earlier in contrast to WT mice (Suppl. Figure 2D). In comparison, simvastatin 
significantly decreased the time for the mice to reach 40 shocks in KO mice, but led only to a 
numerical decrease in WT and OE mice (Suppl. Figure 2D). No differences were observed 
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2.5 Simvastatin did not change the metabolic respiratory measurements during exercise.
We also examined O2 consumption (VO2) and CO2 production (VCO2) by the mice during 
exercise, as these parameters can serve as indicators for substrate utilization during exercise 
(Suppl. Figures 3A and 3B). We then calculated the respiratory exchange ratio (RER), which 
indicates preference for fatty acids when close to 0.7 and preference for glucose as substrate 
when close to 1. OE mice had an RER between 0.8 and 0.9 over the entire exercise period 
irrespective of treatment with simvastatin, indicating a preference for fatty acids as a fuel. In 
comparison, the RER of KO and WT mice were between 0.9 and 1.1, indicating a preference for 
glucose (Suppl. Figure 3C). As shown in Suppl. Table 1, the averaged RER at different time 
points confirm that the RER in OE mice were lower compared to KO and WT mice and they show 
that simvastatin did not significantly affect the RER. These findings correlate well the plasma 
lactate concentrations, which were lower in OE mice compared to WT and KO mice (Figures 2C-
2E).
2.6 PGC-1 over-expression protected impairments of mitochondrial respiration produced 
by simvastatin in glycolytic and oxidative skeletal muscles.
As a next step, we evaluated the mitochondrial function of the glycolytic gastrocnemius and of the 
oxidative soleus muscles. In both muscles, oxidation rates were higher for OE mice than for WT 
or KO mice (Figure 3). In the glycolytic gastrocnemius muscle, simvastatin decreased the 
maximal respiratory rates for complex I + II linked substrates in WT mice (Figure 3A) and for 
complex I linked respiration in KO mice (Figure 3B). In contrast, simvastatin did not affect the 
respiration of the gastrocnemius muscle from OE mice (Figure 3C). In the oxidative soleus 
muscle, mitochondrial respiration was not affected by simvastatin in WT mice (Figure 3D), but 
decreased complex I+II and complex II linked substrate respiration in soleus muscle from KO 
mice (Figure 3E). In the soleus muscle of OE mice, simvastatin did not significantly affect 
mitochondrial respiration (Figure 3F).
2.7 PGC-1 over-expression abolished the increase of mitochondrial H2O2 production and 
free radical leak produced by simvastatin in glycolytic skeletal muscles.
As elevated mitochondrial H2O2 production can be deleterious to mitochondrial function 19, we 
next assayed this in our mice. Under reverse electron flux conditions, simvastatin increased 
mitochondrial H2O2 production in glycolytic white gastrocnemius, but not in soleus of WT mice 
(Figure 4A). In KO mice, H2O2 production was already at a high level in both treatment groups in 
white gastrocnemius in comparison to the respective WT mice and simvastatin did not further 
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mice (Figure 4C). We also calculated the free radical leak (FRL) by relating H2O2 production to 
mitochondrial respiration. As expected, the FRL was lowest for both soleus and gastrocnemius in 
OE mice and highest in KO mice (Figures 4D, 4E and 4F). Similar to H2O2 production, simvastatin 
increased the FRL only in gastrocnemius of WT mice (Figure 4D).
2.8 PGC-1 protected skeletal muscle from simvastatin-induced oxidative stress.
A long-term increase in mitochondrial production of ROS can induce the antioxidative defense 
system. For that, we measured the mRNA expression of Sod1 located in the cytosol and the 
mitochondrial intermembrane space and of Sod2 located in the mitochondrial matrix 20. In 
glycolytic and oxidative parts of gastrocnemius muscle, Sod1 mRNA expression increased in WT 
mice treated with simvastatin (Figures 5A and 5B). In KO mice, simvastatin decreased Sod1 
mRNA expression in both muscles (Figures 5A and 5B). In OE mice, simvastatin increased Sod1 
mRNA expression in the oxidative part of gastrocnemius muscle (Figure 5B), but had no 
significant effect in the glycolytic gastrocnemius (Figure 5A). SOD2 degrades superoxide anion 
and can be upregulated under conditions of increased mitochondrial ROS production 21. 
Simvastatin treatment increased the Sod2 mRNA expression in white and red gastrocnemius in 
WT mice (Figures 5C and 5D). However, in KO mice, simvastatin decreased Sod2 mRNA 
expression in both muscle types (Figures 5C and 5D). In OE mice, Sod2 mRNA expression was 
2 to 3 times higher than in WT or KO mice, but was not affected by simvastatin in both muscle 
types (Figures 5C and 5D). 
H2O2 generated by superoxide dismutation can be degraded to water by glutathione peroxidase in 
a reaction using glutathione. For this reason, we measured the glutathione pool in both 
gastrocnemius muscle types (Figures 5E and 5F). In WT mice, simvastatin did not affect the 
glutathione pool in glycolytic gastrocnemius muscle, but decreased it significantly in oxidative 
gastrocnemius. In comparison to WT mice, the glutathione pool in white gastrocnemius was 
significantly lower in KO mice (Figure 5E). However, simvastatin did not alter the glutathione pool 
in KO mice (Figure 5E). In OE mice, simvastatin treatment did not change the glutathione pool in 
the glycolytic and oxidative the gastrocnemius (Figures 5E and 5F).
2.9 Simvastatin did not affect citrate synthase activity in skeletal muscles. 
We measured citrate synthase activity (CS) and the mtDNA content as markers of mitochondrial 
content 22. As expected, both citrate synthase activity and the mtDNA content normalized to 
muscle weight were higher in OE control compared to WT mice (in red gastrocnemius, the 
increase in citrate synthase activity was only numerical) (Figures 6A-6D). In comparison, citrate 
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reaching statistical significance (Figures 6C and 6D). Simvastatin did not significantly affect 
citrate synthase activity and mtDNA content in white and red gastrocnemius, independently of 
PGC-1α expression. 
2.10 Simvastatin induced changes in the mitochondrial cross area distribution. 
In order to investigate mitochondrial number and cross section distribution, we performed an 
electron microscopy analysis of the glycolytic and oxidative quadriceps muscle. In the glycolytic 
quadriceps muscle, the number of mitochondria was higher in OE as compared to WT and KO 
mice (Suppl. Figure 4A). In the glycolytic quadriceps muscle, simvastatin did not affect the 
number of mitochondria (Suppl. Figure 4A). In the oxidative quadriceps, the number of 
mitochondria was lower in KO compared to WT mice and there was no difference between WT 
and OE mice (Suppl. Figure 4B). In oxidative quadriceps muscle, simvastatin decreased the 
number of mitochondria in WT, but not in KO or OE mice (Suppl. Figure 4B). 
Next, we evaluated the cross-sectional area of the individual mitochondria in each micrograph 
(Figure 7). Compared to WT or KO control mice, OE control mice had a larger median cross-
sectional area (0.30 µm2 for both glycolytic and oxidative skeletal muscle; Figures 7D and 7H) as 
compared to KO (0.09 µm2 and 0.14 µm2 in glycolytic and oxidative muscle, respectively; Figures 
7C and 7G) and WT mice (0.15 µm2 and 0.13 µm2 in glycolytic and oxidative muscle, 
respectively; Figures 7B and 7F). In WT mice, simvastatin decreased the median mitochondrial 
cross-sectional area in both glycolytic (from 0.15 µm2 to 0.08 µm2; Figure 7B) and in oxidative 
quadriceps muscle (from 0.13 µm2 to 0.09 µm2; Figure 7F). In KO mice, treatment with 
simvastatin had no relevant effect on the mitochondrial cross-sectional area in glycolytic 
quadriceps (0.15 µm2 and 0.13 µm2 in control and simvastatin-treated mice, respectively; Figure 
7C), whereas it decreased the cross-sectional area in oxidative quadriceps (0.14 µm2 and 0.11 
µm2 in control and simvastatin-treated mice, respectively; Figure 7G). In OE mice, simvastatin 
had no relevant effect on the mitochondrial cross-sectional area in glycolytic quadriceps (0.30 
µm2 and 0.29 µm2 in control and simvastatin-treated mice, respectively; Figure 7D), whereas it 
increased the cross-sectional area in oxidative quadriceps from 0.30 µm2 to 0.49 µm2 (Figure 
7H).
3 Discussion
The principle goal of this study was to investigate the effect of simvastatin on myotoxicity of mice 
with different skeletal muscle expression of PGC-1α. The hypothesis was that a high expression 
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treatment with simvastatin impaired skeletal muscle function and metabolism mainly in WT and 
PGC-1α KO mice, whereas PGC-1α OE mice were mostly unaffected. The study therefore 
supports the hypothesis that PGC-1α has a protective role in simvastatin-induced myotoxicity.
We treated mice with an oral simvastatin dose of 5 mg/kg/day for three weeks, which should lead 
to similar exposures as observed in humans 18. The dose was calculated as described by 
Reagan-Shaw et al. 23 and corresponds to approximately to 0.4 mg/kg/day in humans, which is a 
dose in the middle range used in humans. We have used the same dose in previous studies, in 
which we observed effects of simvastatin on skeletal muscle and heart metabolism 24,25. The peak 
plasma concentrations in mice determined in the current study (ranging from 1.88 to 21.3 nM) 
were lower than those reported in patients treated with 40 mg simvastatin/day, who have peak 
concentrations in the range of 19-31 nM 18. Importantly, we did not observe significant differences 
in the exposure to simvastatin among the treatment groups, indicating that the groups are 
comparable. In vitro toxicity in mouse skeletal muscle myotubes (C2C12 myotubes) typically starts 
at about 10 µM 25,26, which is higher than the peak concentrations in mice. It has to be taken into 
account, however, that the concentrations reached in muscle may be higher than in plasma and 
that immortalized cell lines may be less sensitive to statins than myocytes in vivo.
We showed that treatment with simvastatin for three weeks at 5 mg/kg/day decreased grip 
strength and exercise capacity in wild-type and in PGC-1α KO mice, but not in PGC-1α OE mice. 
In agreement with the current study, we reported in a previous publication that treatment of rats 
with atorvastatin at 10 mg/kg/day for two weeks decreased exercise capacity 9 and treatment of 
mice with atorvastatin at 5 mg/kg/day for two weeks decreased mice strength assayed by the grip 
test 27. These findings confirm that the skeletal muscle of rodents is sensitive to statins. In the 
current study, simvastatin not only decreased the running distance in WT and PGC-1α KO mice, 
but also increased the post-exercise plasma lactate concentration compared to the respective 
control mice. This suggested a switch from mitochondrial generation of ATP to glycolysis; an 
interpretation, which was supported by the observation that simvastatin increased the RER only 
in WT and PGC-1α KO mice, but not in PGC-1α OE mice. The reason for the switch from 
mitochondrial ATP generation to glycolysis may be a decrease in mitochondrial function by 
simvastatin, as shown in the current but also in previous studies 3,7,27-29. In the current study, we 
found decreases in the activity of complex I and II-linked substrates, which is compatible with an 
impaired activity of complex I and II or also of complex III. A decrease in complex III activity by 
simvastatin has been described by Schirris et al. 3. An impaired activity the electron transport 
chain, in particular of complex I or III, is a well-established reason for mitochondrial production of 
reactive oxygen species (ROS) 30. Indeed, in the current study, we observed an increase in 
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OE mice. Increased mitochondrial production of ROS in association with statins has been 
described in previous studies 15,27,28,31. Since the antioxidative capacity is lower in white than in 
red muscle 31, the finding that only the white gastrocnemius was affected, is not surprising. H2O2 
production was not increased by simvastatin in PGC-1α KO mice, possibly because the 
production was already high in the absence of simvastatin. In comparison, the H2O2 production by 
white gastrocnemius muscle fibers from PGC-1α OE mice was low and not increased by 
simvastatin, suggesting that PGC-1α overexpression was protective. The protection against 
mitochondrial ROS in PGC-1α OE mice may have been mainly due to Sod2, which had a clearly 
higher expression in red and white gastrocnemius compared to WT and PGC-1α KO mice. 
Importantly, an increased intramitochondrial ROS concentration can impair the function of the 
enzyme complexes located in the inner mitochondrial membrane, in particular of complex I, III 
and IV, due to peroxidation of cardiolipin. Cardiolipin is important for the embedment of these 
enzyme complexes in the inner mitochondrial membrane and also for their function 32. This 
mechanism could explain the impairment of the function of the mitochondrial electron transport 
chain by statins.
PGC-1α is an inducible co-regulator of nuclear transcription factors that are involved mainly in 
energy metabolism 33. As confirmed by the current study, mice with whole body 34 or muscle-
specific 16 knock-out of PGC-1α showed a reduced exercise capacity. In comparison, mice with a 
muscle specific over-expression of PGC-1α had an increased exercise capacity 35. The 
improvement of skeletal muscle performance in mice with muscular overexpression of PGC-1α 
can be explained by an increase in the mitochondrial volume fraction and mitochondrial function 
as well as by a shift from glycolytic to oxidative muscle fibers 16. In agreement with these previous 
observations, we detected an increase in the activity of the enzyme complexes of the electron 
transport chain mainly in white (glycolytic), but also in red (oxidative) muscle fibers from PGC-1α 
OE mice. An obvious explanation for these findings is the increase in the mitochondrial copy 
number and volume fraction that we observed in the glycolytic and oxidative muscle of PGC-1α 
OE mice. We have shown in a previous study that atorvastatin can induce a shift from an 
oxidative to a glycolytic fiber type in skeletal muscle of mice 27. We considered this fiber shift to be 
one of the reasons for statin-induced myotoxicity, since glycolytic fibers have less antioxidative 
capacity and are more vulnerable to statins 4,26. On the other hand, as stated above, muscle-
specific overexpression of PGC-1α in mice leads to a shift from glycolytic to oxidative fibers 30,36. 
Since statins exert their myotoxicity at least partially via increased mitochondrial production of 
ROS 15,28,31, this switch from glycolytic to oxidative muscle fibers could possibly explain the 
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Interestingly, PGC-1α OE mice not only had more, but also larger mitochondria. While 
simvastatin decreased the size of mitochondria in WT and PGC-1α KO mice, this was not the 
case in PGC-1α OE mice. The decrease in mitochondrial size in WT and PGC-1α KO mice may 
represent mitochondrial fission, which may be a consequence of mitochondrial toxicity of 
simvastatin. If mitochondrial toxicity by statins is mainly due to increased production of ROS 
15,28,31, mitochondria in PGC-1α OE mice may be protected by the observed increase in Sod2 
mRNA expression levels. This increase appears to be more accentuated than the increase in the 
mitochondrial DNA content or volume fraction, suggesting that PGC-1α overexpression not only 
stimulates mitochondrial biogenesis, but may also affect certain aspects of mitochondrial function.
In conclusion, treatment with simvastatin reduced grip strength and exercise performance in WT 
and PGC-1α KO mice, whereas PGC-1α OE mice were protected. Simvastatin increased ROS 
production in the glycolytic muscle of WT mice, but not of PGC-1α OE mice, which may have 
been protected by a high expression of Sod2. Simvastatin impaired the function of enzyme 
complexes of the mitochondrial electron transport chain in WT and PGC-1α KO mice, but not in 
PGC-1α OE mice. Muscular overexpression of PGC-1α protected mice from simvastatin-induced 
myotoxicity by a switch from glycolytic to oxidative muscle fibers, which have a higher 
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4 Materials and methods
4.1 Animals
The three mouse models used for the purpose of the study include the PGC-1α muscle knockout 
mice (KO), mice with skeletal muscle PGC-1α overexpression (OE) and wild-type mice (WT). 
These breeding pairs of these mouse models were kindly provided by Prof. Handschin (University 
of Basel, Switzerland). Generation of knockout (KO) mice using the Cre/LoxP system by „floxing“ 
Ppargc1a allele has been described previously 36. Breeding was performed by crossing female 
floxed Ppargc1a allele homozygote mice expressing Cre recombinase with male floxed Ppargc1a 
homozygote which did not express Cre recombinase. Cre recombinase was selectively 
expressed in muscle tissues due to its position at the DNA level under the control of the 
myogenin promoter and MEF2C enhancer 37. PGC-1α overexpressing mice with myogenin 
promotor sequence were generated using the DNA microinjection technique. These mice have 
Ppargc1a expression under the control of the muscle creatine kinase promotor preferentially 
expressed in type II fibers 35. Wild type (WT) mice used in experiments included mice with floxed 
Ppargc1a allele homozygotes which did not express Cre recombinase and OE mice which did not 
overexpress the Ppargc1a gene.
4.2 Study design and simvastatin administration
Experiments were performed on adult mice (15-17 weeks at the beginning of the study). Animals 
were housed in neutral temperature environment (22° ± 2 °C) on a 12:12 hour photoperiod and 
had free access to food and water. All experiments were performed in agreement with the 
guidelines from Directive 2010/63/EU of the European Parliament on the protection of animals 
used for scientific purposes. Experiments were reviewed and accepted by the cantonal veterinary 
authority of Basel and were performed in agreement with the guidelines for care and use of 
laboratory animals (License 2847). 
After one week of acclimatization, mice of each model were randomly divided in 6 groups as 
follows: (1) WT treated with water (Ctl, n=10); (2) WT treated with simvastatin 5 mg/kg/day (Simv, 
n=10); (3) KO mice treated with water (n=10); (4) KO mice treated with simvastatin 5 mg/kg/day 
(n=10), (5) OE mice treated with water (n=10); and (6) OE mice treated with simvastatin 5 
mg/kg/day (n=10). These mice were treated by oral gavage for three weeks 26. Body weight, food 
and water intake were measured daily during the treatment period.
4.3 Simvastatin concentration in plasma 
For the measurement of simvastatin in mouse plasma, we treated 4 mice per group one hour 
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concentration (Tmax) 38. Simvastatin acid was analysed in mouse plasma by high-pressure liquid 
chromatography tandem mass spectrometry (HPLC-MS/MS). A HPLC system from Shimadzu 
(Kyoto, Japan) which was connected to a triple quadrupole mass spectrometer from AB Sciex 
(API 4000 Qtrap, Concord, Canada) was used for the measurements. Calibration lines of 
simvastatin acid were prepared in drug free mouse plasma from 0.5 nM (lower limit of 
quantification (LLOQ)) to 200 nM. Unknown samples were quantified based on linear regressions 
of known simvastatin acid concentration (x) and the peak area ratio of simvastatin to simvastatin 
acid-d6 (y). Regressions were weighted by 1/x2. Aliquots of 10 µL plasma were extracted with 
200 µL methanol containing 100 nM simvastatin acid-d6 (internal standard (IS)). Samples were 
thoroughly vortex mixed and centrifuged for 30 min at 3220 g and 15° C. Water and methanol 
plus 0.1% formic acid were used as mobile phase A and B, respectively. Samples were loaded 
with 20% mobile phase B at a flow rate of 0.2 mL/min and temperature of 45° C onto the 
analytical column (Kinetex C18 2.1x50mm, Phenomenex, California, USA). The flow was 
increased to 0.6 ml/min during the first 0.5 min of each run. In the same time, the introduced 
sample was inline diluted via a T-union with mobile phase A at a flow rate gradient of 0.4 to 0 mL 
x min-1 over 0.5 min. Afterwards, mobile phase B was linearly increased to 95% (0.5 to 2.5 min) 
and kept at this percentage for 1 minute. The system was reconditioned at 20% mobile B at the 
end of the run (3.5-4.0 min). Simvastatin acid and simvastatin acid-d6 eluted after 2.6 min. Both 
analytes were detected by electrospray ionization in the negative mode. The mass transition 
435.3 → 318.8, 115.0 m/z and 441.2 → 319.2, 121.2 m/z were applied for simvastatin acid and 
simvastatin acid-d6 analysis, respectively. The following mass transition specific potentials were 
used: Declustering potential (DP) -105, collision energy (CE) -26 V, collision cell exit potential 
(CXP) -117 V for 435.3 → 318.8 m/z; DP of -105 V, CE -40 V, and a CXP of -5 V for 435.3 → 
115.0 m/z; DP -110 V, CE -26 V, CXP -19 V for 441.2 → 319.2 m/z; DP -110 V, CE -44 V, CXP -
7 V for 441.2 → 121.2 m/z. The curtain gas was 10, collision gas was 4, ion sourced gas 1 was 
60, ion source gas 2 was 50, ionspray voltage was -4200 V, entrance potential was -10 V, and 
the source temperature was 500 °C. The LC-MS/MS system was operated and data quantified 
using Analyst software 1.6.2 (AB Sciex, MA; USA).
4.4 Grip strength test
Grip strength, which is a validated parameter of muscle force 39, was measured on hind- and 
forelimbs using a grip strength test meter at days 1, 8, 14, and 22 over the treatment (Bioseb, 
Vitrolles, France). In order to measure their grip strength, the mouse was placed on the top of the 
grid and gently pulled by the tail down the grid using roughly the same pulling force and angle as 
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peak grip force of both fore- and hindlimbs was measured. For each day grip strength was 
measured, it was normalized to body weight of that day. Subsequent grip strength 
measurements, during treatment, were compared to their initial grip strength at day 1 (set to 
100%). All tests were performed blinded by the same operator.
4.5 Treadmill exercise
Mice were submitted to exhaustive exercise by incrementally increasing the speed on a treadmill 
(Treadmill Control, Panlab, Barcelona, Spain) with an electric grid. The electric grid, used to 
encourage the mice to run, delivered an electric shock with 0.4 mA current and 2 Hz frequency. 
This shock only causes an uncomfortable sensation but does not injure the mice. Mice were 
acclimatized to the apparatus for 2 consecutive days before the experiment. The acclimatization 
was performed as a 5-minute training at a speed of 17 cm/s and a slope of +10°. On the day of 
the experiment, a gas analyser was calibrated and the mice were placed in a hermetically sealed 
treadmill. Room air was pumped in and cage air was pumped out to the gas analyser. During the 
first 5 minutes, only room air and basal cage air with the mice were analysed by measuring 
oxygen consumption and carbon dioxide production. Afterwards, the treadmill session started at 
17 cm/s for 5 minutes at a slope of +10°, followed by incremental increase of the speed by 2 cm/s 
every 2 minutes until exhaustion. Exhaustion was defined as continuous 5 seconds shock time 
due to inability of the mouse to run up the treadmill from the electric grid 40. Blood lactate 
concentrations were determined in a sample collected from the tip of the tail before, and 
immediately after exercise using a lactate pro-LT device (Lactate Pro LT-1710, Arkray®, France). 
During the whole exercise session, the running distance and the number of shocks were 
determined. Oxygen consumption and carbon dioxide production were measured and used to 
calculate the respiratory exchange ratio (RER). RER is the ratio of the volume of carbon dioxide 
produced per minute divided by the volume of oxygen consumption over the same period of time. 
The RER is an indicator of substrate utilization: a RER at 0.7 indicates primarily oxidative of fatty 
acid, while a RER 1 represents primarily glucose metabolism 40. Vertical mechanical work and 
power were calculated as previously described 40. All tests were performed blinded by the same 
operator.
4.6 Sample collection
After 3 weeks of treatment, mice were anesthetized with an intraperitoneal injection of ketamine 
(160 mg/kg, Ketasol, Graeub, Bern, Switzerland) and xylazine (20 mg/kg, Rompun, Bayer, 
Leverkusen, Germany). Blood was removed from the apex of the heart and placed in a tube 
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minutes at 4 °C. Tissues were immediately collected and weighed. A part of each muscle tissue 
was immediately frozen in isopentane cooled by liquid nitrogen and stored at -80 °C for later 
analysis and the remainder processed biochemical analysis. We conducted our experiments on 
different muscles, separating them by muscle type. Muscles are classified by mitochondrial 
mass: we used the superficial part of the gastrocnemius, and quadriceps muscle, which are 
mostly glycolytic (white), with a low mitochondrial content. For the oxidative-type muscles (red) 
with a high mitochondrial content, we studied the soleus muscle, the most oxidative red part of 
the gastrocnemius muscle located close to the soleus muscle, and the most oxidative red part of 
the quadriceps muscle located close to femur bone 31.
4.7 Mitochondrial respiration in permeabilized fibers
This technique ensured determination of global mitochondrial function, reflecting both the density 
as well as the functional properties of the muscle mitochondria. For this reason, we used 
saponin-skinned fibers, which kept mitochondria in their architectural environment, in superficial 
gastrocnemius, and soleus muscles as previously described 40,41. Immediately after the sacrifice, 
the oxidative soleus muscle and the glycolytic superficial part of the gastrocnemius muscle were 
excised, cleaned of adipose and connective tissues under binocular microscope, and stored in ice 
cold Biops buffer containing 2.77 mM CaK2-EGTA buffer, 7.23 mM K2-EGTA, 5.77 mM Na2ATP, 
6.56 mM MgCl2 (6H2O), 20 mM taurine, 15 mM Na2 Phosphocreatine, 20 mM imidazole, 0.5 mM 
dithiothreitol, and 50 mM MES hydrate, pH 7.1 at 4°C. Fibers were then washed for 30 min in 
Biops containing saponin (5 μg/mL) to permeabilize the fibers. To wash off excess saponin, fibers 
were washed two times for 5 minutes in the respiration medium (0.5 mM EGTA, 3 mM MgCl2 
(6H2O), 20 mM taurine, 10 mM KH2PO4, 20 mM HEPES, 110 mM D-sucrose, 0.1 % bovine serum 
albumin, and 60 mM lactobionic acid; pH=7 at room temperature). Approximately 2-3 mg of fibers 
were placed in a thermostated oxygraphic chamber containing fresh respiration medium at 37°C 
with continuous stirring (Oxygraph-2k, Oroboros instruments, Innsbruck, Austria). After the 
determination of the basal oxygen consumption with glutamate (5 mM) and malate (2 mM), 
complex I substrate state was measured in the presence of saturating amount of adenosine 
diphosphate (2 mM ADP). The maximal OXPHOS respiration rate was then measured by adding 
succinate, as a substrate of complex II (25 mM). Complex I was then blocked with rotenone (0.5 
µM), allowing to measure complex II-linked substrate state. Afterwards, complex II and complex 
III were inhibited by the injection of malonate (5 mM), and antimycin A (2.5 μM), respectively. 
Continuing the stepwise addition, cytochrome c (10 μM) was added to test for intactness of outer 
mitochondrial membrane. Complex IV-linked respiration was measured by adding N,N,N′,N′-









This article is protected by copyright. All rights reserved
KCN (1 mM) as previously described 40. Respiratory rates were expressed as pmol O2 x s-1 x mg-1 
wet weight.
4.8 Mitochondrial H2O2 production in permeabilized fibers
H2O2 production was studied from saponin-skinned fibers that keep mitochondria in their 
architectural environment, in superficial gastrocnemius, and soleus muscles. The permeabilized 
muscle bundles were placed in ice-cold buffer Z containing 110 mM K-methane sulfonate, 35 mM 
KCl, 1 mM EGTA, 5 mM K2HPO4, 3 mM MgCl2, 6 mM H2O, 0.05 mM glutamate, and 0.02 mM 
malate with 0.5 mg/ml BSA (pH 7.1, 295 mOsmol/kg H2O). H2O2 production was measured with 
Amplex Red (Invitrogen Life Technologies, Rockville, MD, USA), which reacts with H2O2 in a 1:1 
stoichiometry catalyzed by HRP (horseradish peroxidase; Invitrogen Life Technologies, Rockville, 
MD, USA) to yield the fluorescent compound resorufin and a molar equivalent of O2 42. Resorufin 
has excitation and emission wavelengths of 563 nm and 587 nm, respectively, and is extremely 
stable once formed. Fluorescence was measured continuously with a Fluoromax 3 (Jobin Yvon) 
spectrofluorometer with temperature control and magnetic stirring. After a baseline (reactants 
only) had been established, the reaction was initiated by adding a permeabilized fiber bundle to 
600 µL of buffer Z. Buffer Z contained 5 mM Amplex Red, 0.5 U/mL HRP, 5 mM glutamate, and 2 
mM malate as substrates at 37°C. Succinate (25 mM) was then added for the measurement of 
H2O2 production under reverse electron flux condition. ADP (2mM) was added in order to 
determine CI+II-linked substrate state H2O2 production for the determination of the Free Radical 
Leak (FRL). At the conclusion of each experiment, the H2O2 production rate was calculated from 
the background-subtracted slope of F/s, which was converted to concentration by using a 
standard curve (made with 1 nM H2O2 stepwise additions inside Z-buffer). H2O2 production rates 
were expressed as pmol x s-1 x mg-1 wet weight.
4.9 Free Radical Leak
H2O2 production and O2 consumption were measured in parallel under similar experimental 
conditions (CI+II-linked substrate state). This allowed the calculation of the fraction of electrons out 
of sequence, which reduce O2 to ROS in the respiratory chain (the percentage of free radical 
leak) instead of reaching cytochrome oxidase to reduce O2 to water 42. Because two electrons are 
needed to reduce one mole of O2 to H2O2, whereas four electrons are transferred in the reduction 
of one mole of O2 to water, the percent of FRL was calculated as the rate of H2O2 production 
divided by twice the rate of O2 consumption, and the result was multiplied by 100.
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Total RNA was obtained from superficial and the oxidative part of the gastrocnemius muscles 
using the RNeasy Fibrous Tissue Mini Kit (QIAGEN Gmbh, Hilden, Germany) according to the 
manufacturer’s instructions. RNA was stored at −80°C until the reverse transcription reaction was 
performed. cDNA was synthetized from 1 µg total RNA with the Omniscript RT kit (QIAGEN 
Gmbh, Hilden, Germany). To perform the real-time PCR reaction, cDNA was mixed with each 
primer (sense and antisense (0.3 µM final concentration), SYBR Green (Roche Diagnostics, 
Mannheim, Germany) as a fluorescent dye and H2O. The real-time PCR measurement of 
individual cDNAs was performed in triplicate using SYBR Green dye to measure duplex DNA 
formation with the ViiA™ 7 Real-Time PCR System (Applied Biosystems, Waltham, MA, USA). 
The primer sequences were designed using information contained in the public database 
GenBank of the National Center for Biotechnology Information (NCBI). The sequences of the 
primer sets used are listed in Suppl. Table 2. Quantification of gene expression was performed by 
the method described in 43, using the 18s gene as the internal control. The amplification efficiency 
of each sample was calculated as described by Ramakers et al. 44.
4.11 Total glutathione by LC/MS
10 mg of muscle tissue was homogenized with Mikro-Dismembrator (Mikro-Dismembrator S, 
Sartorius, Palaiseau, France) for 30 seconds at 2000 rpm. Tissue samples were solubilised and 
incubated on ice for 30 minutes with 25 μL per 10 mg tissue in a derivatization solution 
(containing 50 mM N-ethylmaleimide (NEM) dissolved in PBS (NEM-PBS)) to inhibit autoxidation 
of the GSH thiol group into GSSG. Methanol was added to the samples in a 1:4 ratio (v/v) to 
precipitate the protein. Samples were then centrifuged for 10 minutes at 4°C with 3500 rpm 
(Eppendorf 5415 R centrifuge, Germany). 250 μL of the supernatant was transferred into a new 
tube containing 250 μL of internal standard (IS, 400 nM GSSG-13C415N2 and 1µM GSH-d5-
NEM dissolved in analytical grade water). Calibration lines of GSH-NEM (250 µM - 0.25 µM) and 
GSSG (25 µM - 0.025 µM) were prepared in the derivatization solution and diluted in methanol in 
a 1:4 ratio and mixed in a new tube with 250 μL of IS. Afterwards, 2.5 μL were injected into the 
LC–MS/MS system (Shimadzu HPLC, Kyoto, Japan, coupled to an API 4000 QTrap tandem 
mass spectrometer, ABSciex, Concord, Canada) to determine the GSH-NEM and GSSG levels in 
mouse skeletal muscle gastrocnemius. GSH-NEM and GSSG were separated on a Symmetry 
Polar C18 analytical column (3.5µM 4.6x75mm (WAT066224, Waters)) at 45 °C and a flow rate of 
0.4 mL/min as previously described 45. Water as a mobile phase A and acetonitrile as a mobile 
phase B were both supplemented with 0.1% acetic acid. Injected samples were then loaded into 
the analytical column by being inline diluted via a T union with mobile phase A during the first 
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reaching 95% of mobile phase B. After each run, the column was washed for 0.5 min with 95% 
mobile phase B and washed again for another 0.75 min at 0% mobile phase B for reconditioning. 
The retention time of GSH-NEM was 1.8 min. The analytes GSH-NEM and GSSG were positively 
charged with ion spray voltage at 5500 eV and probe temperature was at 700 °C. Afterwards, 
they were analyzed with scheduled multiple reaction monitoring. The mass for GSH-NEM was at 
433.1 → 304.0 m/z and for GSH-NEM-d5 was at 438.1 → 304.1 m/z. Total glutathione represents 
the sum of reduced GSH and oxidized GSSG. 
4.12 Mitochondrial DNA (mtDNA) content
Approximately 5 mg of muscle tissue from white or red gastrocnemius was used for DNA 
extraction using the Nucleospin Tissue kit (Nucleospin Tissue, Macherey Nagel, Düren, 
Germany) as per manufacturer’s instructions. Then, DNA samples were diluted to 10 ng/μL from 
which 1 μL was used for the quantitative real-time RT-PCR as described with some modifications 
46. To perform the real-time PCR reaction, diluted DNA was mixed with each primer (forward and 
reverse each containing 0.3 µM final concentration), SYBR Green (Roche Diagnostics, 
Mannheim, Germany) as a fluorescent dye and H2O. The real-time PCR measurement of 
individual cDNAs was performed in triplicate using SYBR Green dye to measure duplex DNA 
formation with the ViiA™ 7 Real-Time PCR System (Applied Biosystems, Waltham, MA, USA). 
Primer sequences used are shown in Suppl. Table 2. PCR run consisted of 40 cycles of 
amplification at 95°C for 15 seconds followed by 1 minute at 60°C. Relative amounts of nuclear 
and mitochondrial DNA were determined by comparison of amplification kinetics of Hexokinase 2 
(Hk2) and Cox2 as described by 47. mtDNA content was assessed by calculating the inverse of 
the CTCox2/CTHk2 ratio 27.
4.13 Citrate synthase (CS) activity
Pieces of frozen muscle (5–10 mg wet weight) were homogenized with a vibrating microbead 
homogenizer (Mikro-Dismembrator, Sartorius®, Palaiseau, France) in a ratio (W/V) of 1/20 with a 
buffer containing 5 mM HEPES, 1 mM EGTA and 1 mM DTT, pH 8.7. The homogenate was then 
supplemented with 0.1% Triton X-100 and incubated on ice for 1 h. After centrifugation for 5 min 
at 3000 rpm, CS activity was determined in the supernatant by spectrophotometry (Tecan M200 
Pro Infinity plate reader, Männedorf, Switzerland) using a 96-well plate as described by Srere 48. 
Values were reported as nmol x min-1 x mg-1 of dry tissue weight.
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A portion of freshly excised muscle (quadriceps femoris) was cut as 0.5 x 0.2 x 0.2 cm strip and 
fixed overnight at 4 °C with 2.5% glutaraldehyde and 2% paraformaldehyde in PIPES buffer (0.1 
M at pH 7). Afterwards, the sample is washed three times with 0.1 M PIPES buffer at pH 7 and 
postfixed in 1% buffered osmium tetroxide for 1h at 4 °C. Then, the sample was rinsed in distilled 
water and placed in an “en bloc” and stained with aqueous uranyl acetate for 1h at 4 °C in the 
dark. Cubes were then dehydrated in an ethanol series (30%, 50%, 75%, 95%, and 100%). The 
dehydrated samples were washed in acetone and finally embedded in Epon 812 resin. 
Embedding was carried out in an 60°C oven for 48h until the epoxy resin was completely 
hardened and ready for sectioning. Ultrathin sections were cut with a diamond knife and placed 
on copper grids coated with Parlodion film and carbon layer impregnated with uranyl acetate and 
lead citrate. Sections were analyzed using a FEI Tecnai T12 transmission electron microscope 
operating at 12 kV. Images were recorded using a TVIPS F416 CMOS digital camera. For the 
quantitative analysis of EM micrographs, non-overlapping 64 μm2 regions were randomly taken 
from transversal sections of the internal part of the quadriceps. Mitochondria were manually 
outlined on the micrographs using the Fiji software 49.
4.15 Statistical analysis
Data are represented as means ± SEM. Statistical analyses were performed using unpaired t 
tests (comparison of 2 unrelated means) or 2-way ANOVA followed by a Bonferroni’s post-test for 
the comparison of multiple means using GraphPad Prism 8 (Graph Pad Software, Inc., San 
Diego, CA, USA). Significance was set at p < 0.05.
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Table 1. Characterization of control (Ctl) and simvastatin-treated (Simv) mice. 
Mouse model WT KO OE
Treatment Ctl Simv Ctl Simv Ctl Simv
Physiological parameter
End study body weight 
(g)
29.3±0.5 29.8±0.8 29.9±0.9 29.0±0.8 28.1±1.0 28.8±0.9
Daily food intake (g) 3.64±0.17 3.67±0.21 3.70±0.14 3.95±0.1 3.56±0.15 3.48±0.08
Daily water intake (mL) 4.45±0.25 4.42±0.33 4.46±0.16 4.54±0.2 4.17±0.25 4.38±0.12
Organ weight (weight per femur length in g x mm-1)
Heart 7.82±0.48 7.46±0.52 7.21±0.44 7.12±0.21 7.42±0.45 7.48±0.21
Gastrocnemius 9.08±0.35 9.26±0.39 9.70±0.41 10.28±0.39 9.08±0.36 9.51±0.36
Soleus 0.44±0.01 0.53±0.01* 0.45±0.03 0.53±0.03 0.53±0.04# 0.51±0.05
EDL 4.11±0.21 4.32±0.14 4.17±0.24 4.36±0.26 4.26±0.06 4.28±0.33
Quadriceps 12.9±0.7 13.5±0.6 12.2±0.9 11.9±0.3 10.8±0.5# 11.5±0.5
WT wild-type mice; KO, muscle PGC-1α knockout mice; OE, muscle PGC-1α overexpression mice; 
EDL, extensor digitorum longus. All values are expressed as mean±SEM with n=10 per group. 
*p<0.05 between simvastatin-treated and control mice, #p<0.05 between the control groups of KO or 
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Figure legends
Figure 1. Grip strength. The grip strength was determined on hind- and forelimbs using a grip 
strength test meter at days 1, 8, 14, and 22 of the treatment period in (A) WT, (B) KO and (C) OE 
mice. The value at day 1 of each treatment group was set at 100%. The operator was blinded 
regarding the treatment of the mice. Data were normalized to body weight and are represented 
as mean ± SEM of 10 animals per group. *p < 0.05 between simvastatin treated and the 
respective control group. Abbreviations: WT, wild type; KO, PGC-1α knock-out mice; OE, PGC-
1α overexpressing mice; Ctl: control; Simv, simvastatin.
Figure 2. Physical capacity. Physical capacity was determined using a treadmill as (A) distance 
until exhaustion and as (B) vertical mechanical power in mice treated or not with simvastatin for 3 
weeks for each mouse model. Blood lactate was determined before and after exhaustive treadmill 
exercise in (C) WT, (D) KO and (E) OE mice. Data are presented as mean ± SEM of 10 animals 
per group. *p < 0.05 between simvastatin-treated and respective control mice. #p < 0.05 between 
control groups of WT, KO and OE mice. Abbreviations: WT, wild type; KO, PGC-1α knock-out 
mice; OE, PGC-1α overexpressing mice; Ctl: control; Simv, simvastatin.
Figure 3. Mitochondrial respiration by permeabilized muscle fibres. Mitochondrial respiratory 
capacity was measured in saponin permeabilized muscle fibres with complex I-, II- and IV-linked 
substrates and their respective inhibitors for glycolytic muscle (white part of gastrocnemius) in (A) 
WT, (B) KO, and (C) OE and for oxidative muscle (soleus) in (D) WT, (E) KO, and (F) OE mice. 
Data are represented as mean ± SEM of 10 animals per group. *p <0.05 between simvastatin-
treated and respective control mice. Abbreviations: WT, wild type; KO, PGC-1α knock-out mice; 
OE, PGC-1α overexpressing mice; Glu/Mal, glutamate/malate; Succ, succinate; Rot, rotenone; 
Malon, malonate; AntiA, antimycin A; TMPD/Asc, N,N,N′,N′-tetramethyl-1,4-
phenylendiamine/ascorbate; Ctl: control; Simv, simvastatin; ww, wet weight.
Figure 4. Mitochondrial H2O2 production in permeabilized muscle fibres. Mitochondrial H2O2 
production by superficial gastrocnemius muscle, and soleus muscle of (A) WT, (B) KO, and (C) 
OE mice. Mitochondrial free radical leak for white gastrocnemius muscle, and soleus muscle of 
(D) WT, (E) KO, and (F) OE mice. Data are represented as mean ± SEM of 10 animals per group. 
*p < 0.05 simvastatin-treated and respective control groups. Abbreviations: WT, wild type; KO, 
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Figure 5. Antioxidative defense in skeletal muscles. Sod1 and Sod2 mRNA expression in the 
white (A and C, respectively) and red (B and D, respectively) part of gastrocnemius. Muscle 
content of total glutathione for the white (E) and red (F) part of gastrocnemius. Data are 
presented as mean ± SEM of 10 animals per group. *p <0.05 between simvastatin-treated and 
control mice. #p < 0.05 between control groups of WT, KO and OE mice. Abbreviations: WT, wild 
type; KO, PGC-1α knock-out mice; OE, PGC-1α overexpressing mice; Ctl: control; Simv, 
simvastatin.
Figure 6. Mitochondrial DNA content and citrate synthase activity in skeletal muscle. 
Mitochondrial DNA quantification in the (A) white part of gastrocnemius and (B) in the red part of 
gastrocnemius. Citrate synthase activity is shown for the white (C) and the red (D) part of 
gastrocnemius normalized to mg tissue weight. Data are presented as mean ± SEM of 10 
animals per group. *p <0.05 between simvastatin-treated and control mice. #p <0.05 the control 
groups of KO or OE mice and WT mice. Abbreviations: WT, wild type; KO, PGC-1α knock-out 
mice; OE, PGC-1α overexpressing mice; Ctl: control; Simv, simvastatin; dw, dry weight.
Figure 7. Mitochondrial cross-section area distribution. Representative electron microscopy 
micrographs for all treatment groups showing sections of white (A) and red (E) quadriceps. The 
frequency distribution of the mitochondrial cross-section area is shown for the white quadriceps 
(WQ) in (B) WT, (C) KO, and (D) OE mice, and for the red quadriceps (RQ) in (F) WT, (G) KO, 
and (H) OE mice. Data are presented as mean ± SEM of 6 separate micrographs per group. The 
white bar in each picture represents 2 m. Abbreviations: WT, wild type; KO, PGC-1α knock-out 
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Suppl. Figure 1. Skeletal muscle mRNA expression of lactate carriers. Expression of 
mRNA was determined by real time PCR as described in Methods. Physical capacity was 
determined as running distance and vertical power using a treadmill. Results were 
normalized to 18s expression and were determined in white gastrocnemius for (A) Mct1 and 
(B) Mct2. Data are presented as mean ± SEM of 10 animals per group. *p <0.05 between 
simvastatin-treated and respective control mice. #p <0.05 between control groups of KO or 
OE mice and WT mice. Abbreviations: WT, wild type; KO, PGC-1α knock-out mice; OE, 
PGC-1α overexpressing mice; Ctl: control; Simv, simvastatin; MCT, monocarboxylate 
transporter. 
 
Suppl. Figure 2. Number of electrical shocks during the treadmill exercise test. 
Physical capacity was determined as running distance and vertical power using a treadmill. 
Mice received non-harmful electrical shocks from a grid at the basis of the treadmill to 
motivate them to run. Total number of shocks received for individual mice are shown for (A) 
WT mice, (B) KO mice and (C) OE mice. The average time to reach 40 shocks is shown in 
(D). Data are presented as individual curves (A – C) or mean ± SEM of 10 animals per 
group. *p <0.05 between simvastatin-treated and respective control mice. #p <0.05 between 
control groups of KO or OE mice and WT mice. Abbreviations: WT, wild type; KO, PGC-1α 
knock-out mice; OE, PGC-1α overexpressing mice; Ctl: control; Simv, simvastatin. 
 
Suppl. Figure 3. Respiratory control ratio (RER) during the treadmill exercise. Physical 
capacity was determined as running distance and vertical power using a treadmill. 
Consumption of oxygen (VO2) and production of CO2 (VCO2) was determined during the 
entire exercise time, allowing us to calculate the RER as VCO2/VO2. (A) Oxygen 
consumption (VO2), (B) CO2 production (VCO2) and (C) RER (VCO2/VO2). The average time 
to reach 40 shocks is shown in (D). Data are presented as individual curves (A – C) or mean 
± SEM of 10 animals per group. *p <0.05 between simvastatin-treated and respective control 
mice. #p <0.05 between control groups of KO or OE mice and WT mice. Abbreviations: WT, 
3 
 
wild type; KO, PGC-1α knock-out mice; OE, PGC-1α overexpressing mice; Ctl: control; Simv, 
simvastatin. 
 
Suppl. Figure 4. Number of mitochondria in white and red quadriceps muscle per area. 
The number of mitochondria was determined morphometrically in muscle sections analyzed 
by electron microscopy in 64 m2. Number of mitochondria per 64 m2 in white quadriceps 
(A) and in red quadriceps (B). Data are presented as mean ± SEM of 6 separate 
micrographs per group. *p <0.05 between simvastatin-treated and respective control mice. #p 
<0.05 between control groups of KO or OE mice and WT mice. Abbreviations: WT, wild type; 





Suppl. Table 1 - Treadmill data of control (Ctl) and simvastatin-treated (Simv) mice. 
 
Mouse model WT  KO OE 
Treatment Ctl Simv Ctl Simv Ctl Simv 
Shock number until exhaustion 
Shocks number 205±26 198±28 80±11 82±13 251±23 285±35 
RER 
Speed (cm x s-1)           
17 0.89±0.03 0.93±0.03 0.97±0.01# 0.93±0.02 0.85±0.02 0.87±0.02 
20 0.89±0.03 0.90±0.02 0.97±0.01 0.93±0.02 0.84±0.02 0.87±0.02 
23 0.90±0.04 0.90±0.03 0.97±0.01 0.94±0.02 0.85±0.02 0.86±0.02 
26 0.92±0.06 0.93±0.04 1.01±0.02 0.96±0.02 0.85±0.02 0.88±0.02 
29 0.91±0.04 0.94±0.04 1.03±0.02# 1.00±0.02 0.86±0.03 0.88±0.02 
32 0.94±0.06 0.94±0.03 1.04±0.02 1.02±0.03 0.85±0.02 0.90±0.02 
35 0.94±0.05 0.94±0.03 1.05±0.03 1.04±0.03 0.88±0.03 0.90±0.02 
38 0.95±0.04 0.96±0.03 1.10±0.04# 1.03±0.01 0.87±0.02 0.90±0.02 
41 1.00±0.06 0.96±0.03   0.87±0.03
# 0.90±0.02 
44 1.04±0.08 0.96±0.02   0.87±0.03
# 0.91±0.01 
47 1.01±0.06 0.96±0.02   0.87±0.02
# 0.91±0.02 
50 1.07±0.04 0.99±0.02 0.87±0.02# 0.92±0.02 
53 0.88±0.02 0.92±0.02 
56     0.88±0.02 0.93±0.02 
WT, wild-type mice; KO, muscle PGC-1α knockout mice; OE, muscle PGC-1α overexpression 
mice. All values are expressed as mean±SEM with n=10 per group. #p<0.05 between the control 




Suppl. Table 2: Primer list for quantitative real-time PCR amplification 
Gene Species Forward primer Reverse primer 
Cox2 Mouse GTT GAT AAC CGA GTC GTT CTG C CCT GGG ATG GCA TCA GTT TT 
Hk2 Mouse GCC AGC CTC TCC TGA TTT TAG TGT 
GGG AAC ACA AAA GAC CTC TTC 
TGG 
Sod1 Mouse GGC AAA GGT GGA AAT GAA GA  GTT TAC TGC GCA ATC CCA AT  
Sod2 Mouse TCA ATG GTG GGG GAC ATA TT  GCT TGA TAG CCT CCA GCA AC  
Mct1 Mouse TGC AAC GAC CAG TGA AGT ATC A ACA ACC ACC AGC GAT CAT TAC T 
Mct4 Mouse AGA GCA CTT AAA GTC GCC CCC GGG CTG CTT TCA CCT GTT ACC 
18s Mouse AGT CCC TGC CCT TTG TAC ACA CGA TCC GAG GGC CTC ACT A 
Cox2, cytochrome oxidase 2; Hk2, hexokinase 2; Sod1, superoxide dismutase 1; Sod2, 
superoxide dismutase 2; Mct1, monocarboxylate transporter 1; Mct4, monocarboxylate 
transporter 4; 18s, 18s ribosome RNA.  
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